Literature DB >> 18446448

Lysergic acid amide-induced posterior reversible encephalopathy syndrome with status epilepticus.

Stephane Legriel1, Fabrice Bruneel, Odile Spreux-Varoquaux, Aurelie Birenbaum, Marie Laure Chadenat, François Mignon, Nathalie Abbosh, Matthieu Henry-Lagarrigue, Laure Revault D'Allonnes, Pierre Guezennec, Gilles Troche, Jean Pierre Bedos.   

Abstract

INTRODUCTION: Posterior reversible encephalopathy syndrome (PRES) is known to occur in association with several substances. However, lysergic acid amide (LSA) is not among the previously reported causes of PRES.
METHODS: We report on a patient with PRES presenting as convulsive status epilepticus associated with hypertensive encephalopathy after LSA ingestion. Magnetic resonance imaging was performed and catecholamine metabolites assayed.
RESULTS: The patient achieved a full recovery after aggressive antihypertensive therapy and intravenous anticonvulsivant therapy. The clinical history, blood and urinary catecholamine levels, and response to treatment strongly suggest that PRES was induced by LSA.
CONCLUSION: LSA, a hallucinogenic agent chiefly used for recreational purposes, should be added to the list of causes of PRES.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18446448     DOI: 10.1007/s12028-008-9096-5

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  64 in total

1.  [Posterior reversible encephalopathy syndrome: about 2 cases related to the cyclosporine].

Authors:  T Lepoivre; M Treilhaud; E Auffray-Calvier; J C Rigal; Y Blanloeil
Journal:  Ann Fr Anesth Reanim       Date:  2003-05

Review 2.  Posterior reversible encephalopathy syndrome in intensive care medicine.

Authors:  Giuseppe Servillo; Francesca Bifulco; Edoardo De Robertis; Ornella Piazza; Pasquale Striano; Fabio Tortora; Salvatore Striano; Rosalba Tufano
Journal:  Intensive Care Med       Date:  2006-11-21       Impact factor: 17.440

3.  A case of oxaliplatin-related posterior reversible encephalopathy syndrome.

Authors:  Matthew R Skelton; Richard M Goldberg; Bert H O'Neil
Journal:  Clin Colorectal Cancer       Date:  2007-01       Impact factor: 4.481

4.  A syndrome of irreversible leukoencephalopathy following pediatric allogeneic bone marrow transplantation.

Authors:  A Yuriko Minn; Paul G Fisher; Patrick D Barnes; Gary V Dahl
Journal:  Pediatr Blood Cancer       Date:  2007-02       Impact factor: 3.167

5.  Erythropoietin-associated hypertensive posterior leukoencephalopathy.

Authors:  N Delanty; C Vaughan; S Frucht; P Stubgen
Journal:  Neurology       Date:  1997-09       Impact factor: 9.910

Review 6.  Molecular, pharmacological and functional diversity of 5-HT receptors.

Authors:  Daniel Hoyer; Jason P Hannon; Graeme R Martin
Journal:  Pharmacol Biochem Behav       Date:  2002-04       Impact factor: 3.533

7.  Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor.

Authors:  J R Bunzow; M S Sonders; S Arttamangkul; L M Harrison; G Zhang; D I Quigley; T Darland; K L Suchland; S Pasumamula; J L Kennedy; S B Olson; R E Magenis; S G Amara; D K Grandy
Journal:  Mol Pharmacol       Date:  2001-12       Impact factor: 4.436

8.  Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.

Authors:  Jeffrey A Allen; Ashish Adlakha; Peter R Bergethon
Journal:  Arch Neurol       Date:  2006-10

9.  Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia.

Authors:  M F Egan; T E Goldberg; B S Kolachana; J H Callicott; C M Mazzanti; R E Straub; D Goldman; D R Weinberger
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

10.  An autopsy case of drug-induced diffuse cerebral axonopathic leukoencephalopathy: the pathogenesis in relation to reversible posterior leukoencephalopathy syndrome.

Authors:  Riki Okeda; Tatsunari Kawamoto; Eri Tanaka; Hideo Shimizu
Journal:  Neuropathology       Date:  2007-08       Impact factor: 1.906

View more
  4 in total

Review 1.  [Headache and hypertension. Myth and evidence].

Authors:  T Liman; E Siebert; M Endres
Journal:  Nervenarzt       Date:  2010-08       Impact factor: 1.214

2.  Determinants of recovery from severe posterior reversible encephalopathy syndrome.

Authors:  Stephane Legriel; Olivier Schraub; Elie Azoulay; Philippe Hantson; Eric Magalhaes; Isaline Coquet; Cedric Bretonniere; Olivier Gilhodes; Nadia Anguel; Bruno Megarbane; Laurent Benayoun; David Schnell; Gaetan Plantefeve; Julien Charpentier; Laurent Argaud; Bruno Mourvillier; Arnaud Galbois; Ludivine Chalumeau-Lemoine; Michel Rivoal; François Durand; Arnaud Geffroy; Marc Simon; Annabelle Stoclin; Jean-Louis Pallot; Charlotte Arbelot; Martine Nyunga; Olivier Lesieur; Gilles Troché; Fabrice Bruneel; Yves-Sébastien Cordoliani; Jean-Pierre Bedos; Fernando Pico
Journal:  PLoS One       Date:  2012-09-14       Impact factor: 3.240

3.  Tacrolimus associated posterior reversible encephalopathy syndrome - a case series and review.

Authors:  Susmitha Apuri; Kristin Carlin; Edward Bass; Phuong Thuy Nguyen; John N Greene
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-02-18       Impact factor: 2.576

4.  Duloxetine-related posterior reversible encephalopathy syndrome: A case report.

Authors:  Nathalie Zappella; François Perier; Fernando Pico; Catherine Palette; Alexandre Muret; Sybille Merceron; Andrei Girbovan; Fabien Marquion; Stephane Legriel
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.